A novel approach to target inflammatory diseases
Inotrem is an advanced clinical stage biotech company specialized in immunotherapy to control inflammatory syndromes.
The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to restore a balanced inflammatory response.
Leveraging its proprietary technology platform, Inotrem has developed nangibotide, a peptide, first-in-class TREM-1 inhibitor, with applications in severe conditions such as septic shock and COVID-19 and is conducting a broad monoclonal antibody program to target chronic inflammation, fibrotic diseases and immuno-oncology.
Inotrem’s deep knowledge of the TREM-1 pathway biology and role in inflammation allows to develop in parallel companion diagnostics tools to select those patients more likely to benefit from the anti-TREM strategies.
Opening a new front in precision medicine for inflammatory conditions
Addressing acute and chronic inflammatory conditions for which there is no effective or limited causal treatment available, Inotrem’s novel therapeutic approach is driven by a sharp entrepreneurial vision and rooted in internationally recognized scientific leadership.
- A unique scientific and medical approach with blockbuster potential
- Successful and highly experienced leadership team with global/international experience
- Advanced science, strong IP positions, prominent R&D partnerships